Get Real Stocks

DNTH · Dianthus Therapeutics

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Country
United States

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

24h Volume by Exchange

No Data Yet

Issuer
Price
$105.47
24h Volume
-
Depth (±1%)
-